Innovative Medicines Canada Welcomes Patrick Hupé as Vice President of Government and Stakeholder Relations

Media Enquiries

media@imc-mnc.ca
613-462-5367

Join media list

Press Release

Ottawa, February 3, 2025 – Innovative Medicines Canada (IMC) is pleased to welcome Patrick Hupé, M.Sc., MBA, as Vice President of Government and Stakeholder Relations, effective today. Patrick brings over 25 years of experience in medical technology and life sciences, including senior roles at Medtronic, Pfizer, and Roche Diagnostics. His appointment underscores IMC’s commitment to deepening collaboration with governments and advancing public policy solutions that strengthen Canada’s healthcare system.

Throughout his career, Patrick has demonstrated exceptional leadership and strategic vision. He has led high-performing, multidisciplinary teams and executed large-scale initiatives to improve access to innovative technologies, partnering with government officials, policymakers, regulatory bodies, and public health leaders. At Medtronic, where Patrick served as Vice President, Strategy & Access for Canada and Latin America, he played a key role in securing an R&D, training, and manufacturing facility through a landmark agreement with the Quebec government, which was awarded “Best Medical Technology Project in the World” by the Financial Times.

“Patrick’s impressive leadership, vast industry knowledge, and commitment to fostering innovation make him an invaluable addition to the IMC team,” said Dr. Bettina Hamelin, President of Innovative Medicines Canada. “As we navigate a rapidly evolving healthcare landscape, Patrick’s insights and expertise will be instrumental in advancing policies that enhance patient care and expand access to life-changing treatments. His experience working with government leaders and stakeholders will ensure IMC remains a trusted partner in shaping policies that benefit all Canadians.”

Patrick holds a Master’s in Molecular Biology from Université de Montréal and an MBA from HEC Montréal. His strong academic foundation in both business and science gives him the unique ability to bridge technical expertise with corporate strategy. Together with IMC’s leadership team, Patrick will drive alignment between industry priorities and government objectives, ensuring that policy frameworks reflect the evolving needs of patients and the healthcare system.

About Innovative Medicines Canada

Innovative Medicines Canada (IMC) is the national association representing Canada’s innovative pharmaceutical industry. The industry proudly supports over 100,000 high-value jobs, contributes a total of $16 billion to the economy, sponsors the majority of clinical trials in Canada, and invests close to $3 billion in research and development each year. IMC advocates for policies that enable the discovery, development, and delivery of innovative medicines and vaccines to improve the lives of all Canadians. The association and its members are committed to being solutions-oriented partners in Canada’s healthcare system and have contributed over $30 million towards applied health systems research through the Health Research Foundation (HRF). Guided by the Code of Ethical Practices, all members work with governments, private payers, healthcare professionals, and stakeholders in a highly ethical manner.

For further information:

Media Relations
media@imc-mnc.ca

resources

Discover. Learn.
Understand.

Informative content to keep you up to date on the most pressing issues facing our industry.